爱威科技股份有限公司 关于获得湖北省科学技术进步奖二等奖的自愿性披露公告

Core Viewpoint - The company has received a scientific and technological achievement award from the Hubei Provincial Government for its project on "Key Technological Innovations and Clinical Applications of Molecular Diagnosis of Acute Leukemia" [1] Group 1: Project Details - Project Name: Key Technological Innovations and Clinical Applications of Molecular Diagnosis of Acute Leukemia [1] - Award: Second Prize of the 2025 Hubei Provincial Scientific and Technological Progress Award [1] - Main Contributors: A list of contributors including Zhou Fuling, Lei Cheng, and others [1] - Collaborating Institutions: Wuhan University, Shanghai Aisai Medical Technology Co., Ltd., Wuhan Kanglu Biological Technology Co., Ltd., Shanghai Jiao Tong University, and the company [1] - The project addresses four major clinical challenges in acute leukemia diagnosis and treatment [1] Group 2: Technological Innovations - The project has developed a comprehensive diagnostic technology system that integrates molecular mechanisms, sampling tools, diagnostic platforms, and clinical applications [1] - It reveals the oxidative stress mechanism driving malignant proliferation of leukemia stem cells through the "ROS-JAB1-TRX" pathway [1] - Innovations include the development of a painless puncture needle and a cryopreservation system, overcoming challenges in sample collection and viability [1] - The project has established a high-reproducibility PDX model and developed gene testing technologies such as EasyCatch and CoHIT, creating a promotable molecular diagnostic process [1] Group 3: Impact on the Company - The award is a recognition of the company's technological innovation and research capabilities [1] - The company plans to increase its research efforts and enhance its core competitiveness through continued technological innovation [1][2]